Brief: Theravance Biopharma and Mylan Enter Into Settlement Agreement With Orbicular Pharmaceutical Technologies

Theravance Biopharma

16/01/2024 11:44

Jan 16 (Reuters) - Theravance Biopharma Inc  TBPH.O :
    * THERAVANCE BIOPHARMA INC: ON JAN 12, THERAVANCE & MYLAN
ENTERED
INTO SETTLEMENT AGREEMENT WITH ORBICULAR PHARMACEUTICAL
TECHNOLOGIES PRIVATE LIMITED
    * THERAVANCE BIOPHARMA INC: SETTLEMENT AGREEMENT RELATING TO
THERAVANCE AND MYLAN'S YUPELRI((REG))(REVEFENACIN) INHALATION
SOLUTION
    * THERAVANCE BIOPHARMA: THERAVANCE & MYLAN GAVE ORBICULAR
NON-EXCLUSIVE LICENSE TO MANUFACTURE, MARKET ORBICULAR'S GENERIC
VERSION OF YUPELRI IN US
    * THERAVANCE BIOPHARMA: LICENSE FOR ORBICULAR'S GENERIC
VERSION OF
YUPELRI IN US STARTS ON OR AFTER LICENSED LAUNCH DATE OF APRIL
23, 2039

Further company coverage:  TBPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))